On March 5, 2026, BriaCell Therapeutics Corp. held its Annual General Meeting where shareholders approved auditor MNP LLP and elected six board members, with a quorum of 3,502,695 shares represented. Additionally, they re-approved the Omnibus Equity Incentive Plan with 1,524,081 votes in favor.